Product Description
DESCARTES-25 is the first off-the-shelf RNA Cell Therapy for cancer. The lead indication is multiple myeloma. DESCARTES-25 is designed to deliver two complementary antitumor proteins directly to the tumor: a novel bispecific antibody that binds B-cell Maturation Antigen (BCMA) with femtomolar avidity and the potent antitumor cytokine interleukin-12 (IL-12). DESCARTES-25 cells are further engineered with a membrane-bound homing protein that directs the cells to the tumor microenvironment for local delivery of their antitumor cargo. (Sourced from: https://www.cartesiantherapeutics.com/clinical-trials/)
Mechanisms of Action: Stem Cell Therapy, IL12
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cartesian Therapeutics
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05113342 |
DC25-1A | P1 |
Terminated |
Multiple Myeloma |
2023-05-09 |
35% |
2024-11-13 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/25/2022 |
News Article |
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma |